XTL shutters program on early-stage failure

XTL Biopharmaceuticals has shuttered the development program for XTL-2125 after it failed to demonstrate efficacy in a Phase I trial for hepatitis C. Viral load reductions proved negligible in comparison to a control group. A total of 56 volunteers were divided into eight groups, two of which received placebo.

- take a look at XTL's announcement on the closure
- here's the report from Globes on the trial failure

Related Articles:
XTL licenses development rights to pain therapy. Report
XTL names Ron Bentsur CEO. Report

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.